BioCentury
ARTICLE | Clinical News

Neflamapimod: Ph IIa Study 303 data

January 20, 2017 7:13 PM UTC

The double-blind, U.S. Phase IIa Study 303 in 8 evaluable patients ages 60-85 with mild cognitive impairment (MCI) due to AD or mild AD showed that twice-daily 40 and 125 mg oral neflamapimod improved...